Schering - Thread

Schering  Übersicht   Kurse   Charts   Fundamental    News   Forum function tool_click() {    var pos = getXYcoord( 'tool_insert_pos' );  var newLyr = (document.layers) ? getObject('tool_insert') : getObject('tool_insert').style;  newLyr.visibility = show;  newLyr.left = pos.x-10;   newLyr.top = pos.y-22;  return false;} var tool_hide_it=1Depot
Watchlist
Vol'Watch

---

KO Map
 Einfügen in... OS Long
OS Short

---

KO Long
KO Short

---

Discount-Zert.
Index-Zert.
Basket-Zert.
Aktienanl.
Garantie-Zer.
 Zugehörige... WKN: 717200 ISIN: DE0007172009   Ansicht:  Unternehmensprofil   GuV / Bilanz   Pro Aktie   Personal   Bewertung   Komplett   Vergleich (Branche)

 StammdatenTickerSCHSektorChemie/Pharma BranchePharmaLandDeutschlandWährungEUROAktientypInlandsaktie
 KontaktAdresseMüllerstr. 178
D-13353 Berlin Postfach- Telefon+49-30-468-1111Fax+49-30-468-15305Internethttp://www.schering.de/E-Mailinvestor.relations@schering.de  AktionärsstrukturAktionärin %Allianz AG10.00Freefloat90.00
 ProfilDie Schering AG ist ein weltweit tätiger forschender Pharma-Konzern. Das Unternehmen erforscht und entwickelt neuartige Arzneimittel. Dabei setzt es verstärkt auf die Entwicklung von innovativen Lösungen durch Biotechnologie und Gentechnik.
 ManagementPersonDr. Hubertus ErlenDr. Ulrich KöstlinLutz LingnauProf. Dr. Dr. h.c. Gunter StockDr. Jörg SpiekerkötterDr. Marc Rubin (ab 01.10.2003)  AufsichtsratPersonDr. Giuseppe VitaNorbert DeutschmannDr. rer. oec. Karl-Hermann BaumannProf. Dr. Piet BorstDr. Mathias DöpfnerProf. John A. DormandyJoachim ElsholzDr. rer. pol. Reiner HagemannJohannes HeitbaumDr. h.c. Martin KohlhaussenHermann-Josef LambertiDr. med. Hans-Peter NiendorfHans-Jürgen ScheelGünter SchmittDr. rer. oec. Ulrich SommerHeinz-Georg Webers

 GuV in Mio. EURO nach IAS 1999200020012002Umsatz3.674,04.493,04.842,05.023,0Bruttoergebnis vom Umsatz2.772,03.404,03.627,03.811,0Operatives Ergebnis (EBIT)536,0640,0668,0741,0Ergebnis vor Steuer (EBT)459,0635,0698,01.145,0Jahresüberschuss/-fehlbetrag272,0336,0418,0867,0
 Bilanz in Mio. EURO nach IAS 1999200020012002Aktiva    Summe Umlaufvermögen2.471,02.961,02.683,03.196,0Summe Anlagevermögen (*)2.158,02.245,02.580,02.196,0Summe Aktiva4.629,05.206,05.263,05.392,0Passiva    Gesamtverschuldung / Gesamtverbindlichkeiten648,0817,0900,0721,0Summe Fremdkapital2.531,02.909,02.707,02.458,0Summe Eigenkapital2.098,02.297,02.556,02.934,0Summe Passiva4.629,05.206,05.263,05.392,0

 Die Aktie: Angaben in EURO 1999200020012002Aktien im Umlauf (in Mio.)-198,0198,0197,3Dividende pro Aktie2,501,000,830,93Dividendenausschüttung in Mio. EURO165,0198,0164,0183,0unverwässertes Ergebnis pro Aktie1,351,702,114,39verwässertes Ergebnis pro Aktie1,351,682,104,38Umsatz pro Aktie-22,724,525,5Jahresendkurs120,860,559,641,5Buchwert pro Aktie-11,612,914,9

 Personal 1999200020012002Personal am Ende des Jahres22.43024.54125.05626.245Personalaufwand in Mio. EURO-1.422,01.531,01.595,0Umsatz je Mitarbeiter in EURO163.798183.081193.247191.388

 Bewertung 19992000200120022003 (**)Jahresendkurs120,860,559,641,538,4Marktkapitalisierung (Mio)0,011.979,011.800,88.178,17.572,4KGV (Kurs/Gewinn)-35,728,29,48,7KUV (Kurs/Umsatz)-2,72,41,61,5KBV (Kurs/Buchwert)-5,24,62,82,6
(*) und langfristige Vermögensgegenstände
(**) auf Basis der Vorjahresbilanz und des VortagskursesAktualisiert am 11.8.2003, powered by

Freundlichst,

Twinson_99

 

 

@ Zick-Zock - hast Du Dir mal die Dax Schering angeschaut? Was hälst Du davon? Weiterhin viel Erfolgt mit Deiner Schering Plough

If so, that complacence has ended. Robert Spiegel, Schering's chief medical officer, says he hopes that the new trial, called IDEAL, will clear up confusion about what differences exist between PEG-Intron and Pegasys. For example, Pegasys is easier to administer because it comes premixed in a single vial, but the drug is given in the same dose no matter what a patient's weight is. The dose of PEG-Intron is changed based on a patient's weight. Not surprisingly, the two companies argue over which dosing scheme is better.

Some doctors have inferred other differences based on seperate clinical trials in which Pegasys and PEG-Intron were compared to standard interferon. Both John McHutchison, director of hepatology research at the Duke Clinical Research Institute, who is heading up the IDEAL trial, and Michael Fried, director of hepatology at the University of North Carolina in Chapel Hill, point out two such inferences. First, studies appear to indicate that Pegasys may have fewer side effects. Also, studies seem to show that Pegasys works better for some patients infected with the strain of hepatitis C that is most common in the U.S. and the most difficult to treat. Both doctors emphasized that such inferences are not definitive, because the drugs had not been directly compared to one another in the same clinical trial.

"Right now you've been listening to a lot of marketing," says David Bernstein, head of hepatology at North Shore University Hospital in Manhasset, N.Y. "But now we're actually going to have some science." He has participated in clinical trials for both Roche and Schering.

It will be years before Schering has any results from the trial. But Raymond James analyst Krensavage says it is possible that just proceeding with the trial could help Schering market the drug by making the firm seem more confident. "We do think that this study makes marketing sense," says Schering's Spiegel, "but it's designed to answer a scientific question that the medical community wants to know."

There are other bright spots for the company. Hassan, who served as chief executive of Pharmacia until that firm was bought by Pfizer (nyse: PFE - news - people ), is known as a turnaround artist. Krensavage says that Schering's new cholesterol medicine, Zetia, could eventually become a big seller; sales would be split with Merck (nyse: MRK - news - people ). But competition in the cholesterol market is intense, with such firms as AstraZeneca (nyse: AZN - news - people ) and Bristol-Myers Squibb (nyse: BMY - news - people ) also fighting hard for market share.

The IDEAL trial, Spiegel says, reflects the kind of things that Schering will be doing under Hassan to better address the needs of its customers. "He's said clearly that he wants us to be a customer-facing organization," says Spiegel, "and I think this is a direct example of how we're going to do that."

Fried, who had done some of the important trials for Roche's Pegasys, and McHutchison both hope doctors will withhold judgment until the new data are in.

"I hope that people would not disregard a lot of published literature that's out there based on a press release saying they're planning on doing a study," says Fried. "Physicians need to go back to the primary sources of literature to make their treatment decisions. These types of studies will be very beneficial for the prescribers of the medicines and the patients who ultimately have to use them."

"We've been talking about this for a long time," McHutchison says. "Could it influence sales? I haven't thought about that; I don't know how to answer that. We're not going to have results of this trial for years. These things take years to perform."





--------------------------------------------------

1 of 1

MfG, ZiZo

Expertenkomitee empfiehlt Schering-Mittel Zevalin zur Zulassung  

   London, 25. Sep (Reuters) - Ein europäischer
Expertenausschuss hat am Donnerstag das neue Krebsmedikament der
Schering AG, Zevalin, zur Zulassung empfohlen.
   Der Expertenausschuss CPMP habe ein positives Votum für das
Medikament abgegeben, teilte die in London ansässige Europäische
Agentur zur Medikamenten-Bewertung mit. Empfehlungen des CPMP
werden üblicherweise von der Europäischen Kommission binnen 90
Tagen gebilligt. Von Schering in Berlin war zunächst keine
Stellungnahme zu erhalten.
   bek/kae

Freundlichst,

Twinson_99